지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
초록· 키워드
오류제보하기
Methoxy polyethylene glycol-epoetin beta (MPG-EPO), a continuous erythropoietin receptor activator, is a new erythropoiesis-stimulating agent with a long half-life. The purpose of this prospective study is to assess the effects of oncemonthly subcutaneous MPG-EPO on hematological responses and nutritional status in peritoneal dialysis patients. Forty four patients undergoing stable peritoneal dialysis were enrolled into the study. Darbepoetin alfa therapy, in peritoneal dialysis patients, was converted to the monthly administration of subcutaneous MPG-EPO for 6 months. The starting dose of MPG-EPO was based on the previous weekly dose of darbepoetin alfa. The dose adjustments were performed to maintain the hemoglobin (Hb) levels in a target range of 10.5-11.0 g/dL. If the Hb levels exceeded 11.0 g/dL, MPGEPO was temporarily interrupted for 1 month. The mean Hb levels were stable with the values of 9.5±1.1 g/dL at baseline,and 10.4±0.9 g/dL at the 6th month after conversion. The mean differences in the changes of Hb levels between the baseline and the 6th month were 0.9±1.4 g/dL, which was statistically significant. However, the mean differences of iron, transferrin saturation and ferritin concentrations were not significant. It did not show significant differences in the changes of the nutritional parameters. These results suggest that the once-monthly subcutaneous administration of MPGEPO for 6 months effectively maintains the Hb levels and nutritional status in peritoneal dialysis patients. Taken together, the once-monthly subcutaneous administration of MPG-EPO was practical and might improve the clinical compliance for the management of renal anemia in peritoneal dialysis patients.
목차
등록된 정보가 없습니다.
참고문헌 (21)
참고문헌 신청
Canadian Erythropoietin Study Group / 1990 / Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialys
Canaud B / 2008 / Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomiz
Curran MP / 2008 / Methoxy polyethylene glycolepoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease / Drugs 68 (8) : 1139 ~ 11
Eschbach JW / 1987 / Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial / N Engl J
Fouque D / 2011 / Nutrition and chronic kidney disease / Kidney Int 80 (4) : 348 ~ 357
Canaud B / 2008 / Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomiz
Curran MP / 2008 / Methoxy polyethylene glycolepoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease / Drugs 68 (8) : 1139 ~ 11
Eschbach JW / 1987 / Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial / N Engl J
Fouque D / 2011 / Nutrition and chronic kidney disease / Kidney Int 80 (4) : 348 ~ 357
이 논문의 저자 정보
최근 본 자료
댓글(0)
0